JP2023546054A5 - - Google Patents
Info
- Publication number
- JP2023546054A5 JP2023546054A5 JP2023522409A JP2023522409A JP2023546054A5 JP 2023546054 A5 JP2023546054 A5 JP 2023546054A5 JP 2023522409 A JP2023522409 A JP 2023522409A JP 2023522409 A JP2023522409 A JP 2023522409A JP 2023546054 A5 JP2023546054 A5 JP 2023546054A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- ring
- substituted
- cases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020120605 | 2020-10-13 | ||
| CNPCT/CN2020/120605 | 2020-10-13 | ||
| CN2021118149 | 2021-09-14 | ||
| CNPCT/CN2021/118149 | 2021-09-14 | ||
| PCT/CN2021/123515 WO2022078380A1 (en) | 2020-10-13 | 2021-10-13 | Heterocyclic glp-1 agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023546054A JP2023546054A (ja) | 2023-11-01 |
| JP2023546054A5 true JP2023546054A5 (cg-RX-API-DMAC10.html) | 2025-01-07 |
Family
ID=81207669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023522409A Pending JP2023546054A (ja) | 2020-10-13 | 2021-10-13 | ヘテロ環glp-1アゴニスト |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240083886A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4229049A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2023546054A (cg-RX-API-DMAC10.html) |
| CN (1) | CN116547278A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022078380A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021219019A1 (en) | 2020-04-29 | 2021-11-04 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| PE20231181A1 (es) | 2020-08-06 | 2023-08-11 | Gasherbrum Bio Inc | Agonistas del glp-1 heterociclicos |
| JP2023538949A (ja) | 2020-08-28 | 2023-09-12 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環glp-1アゴニスト |
| JP7812052B2 (ja) | 2020-09-01 | 2026-02-09 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 縮合イミダゾール誘導体、その調製方法及びその医薬的応用 |
| TWI843104B (zh) | 2021-05-20 | 2024-05-21 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| KR20240053617A (ko) | 2021-08-30 | 2024-04-24 | 민드랭크 에이아이 리미티드 | Glp1r 작용제로서의 신규 아릴 에테르 치환 헤테로시클릭 화합물 |
| KR20240056719A (ko) | 2021-09-08 | 2024-04-30 | 시오노기 앤드 컴파니, 리미티드 | 항비만 작용이 관여하는 질환의 예방 및 치료용 의약 |
| SI4408840T1 (sl) | 2021-09-27 | 2025-12-31 | Terns Pharmaceuticals, Inc. | Benzimidazolne karboksilne kisline kot agonisti GLP-1R |
| US20250236627A1 (en) | 2021-10-05 | 2025-07-24 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| WO2023057427A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators |
| WO2023057429A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| US12024507B2 (en) | 2021-10-25 | 2024-07-02 | Terns Pharmaceuticals, Inc. | Compounds as GLP-1R agonists |
| US20250066338A1 (en) | 2021-12-16 | 2025-02-27 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| US20250042882A1 (en) | 2021-12-16 | 2025-02-06 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| AU2023224854A1 (en) | 2022-02-23 | 2024-10-03 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| CN119923395A (zh) * | 2022-07-27 | 2025-05-02 | 卡莫特医疗有限公司 | N-杂环gpcr受体激动剂、包含其的药物组合物和其使用方法 |
| CN119907794A (zh) | 2022-09-22 | 2025-04-29 | 盐野义制药株式会社 | 具有glp-1受体激动剂作用的稠环化合物 |
| WO2024102625A1 (en) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
| CR20250178A (es) | 2022-11-16 | 2025-06-06 | Lilly Co Eli | Agonistas del receptor del péptido-1 similar al glucagón |
| PE20252787A1 (es) | 2023-04-07 | 2025-12-22 | Terns Pharmaceuticals Inc | Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica |
| EP4777197A2 (en) | 2023-09-14 | 2026-07-22 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2686379A1 (en) * | 2007-05-04 | 2008-11-13 | Irm Llc | Phenylaminopyrimidine derivatives and compositions thereof as c-kit and pdgfr kinase inhibitors |
| CN107207444B (zh) * | 2014-11-26 | 2020-07-24 | 武田药品工业株式会社 | 二环化合物 |
| CN108017636A (zh) * | 2016-11-04 | 2018-05-11 | 合帕吉恩治疗公司 | 作为fxr调节剂的含氮杂环化合物 |
| WO2018109607A1 (en) * | 2016-12-16 | 2018-06-21 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| FI3806855T3 (fi) * | 2018-06-15 | 2023-05-04 | Pfizer | Glp-1 -reseptorin agonisteja ja niiden käyttöjä |
| EA202191432A1 (ru) * | 2018-11-22 | 2021-10-14 | Цилу Регор Терапьютикс Инк. | Агонисты glp-1r и их применения |
| ES3029360T3 (en) * | 2019-11-15 | 2025-06-24 | Ildong Pharmaceutical Co Ltd | Glp-1 receptor agonist and use thereof |
-
2021
- 2021-10-13 WO PCT/CN2021/123515 patent/WO2022078380A1/en not_active Ceased
- 2021-10-13 CN CN202180082168.XA patent/CN116547278A/zh active Pending
- 2021-10-13 EP EP21879423.8A patent/EP4229049A4/en active Pending
- 2021-10-13 JP JP2023522409A patent/JP2023546054A/ja active Pending
- 2021-10-13 US US18/248,858 patent/US20240083886A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023546055A5 (cg-RX-API-DMAC10.html) | ||
| JP2023537501A5 (cg-RX-API-DMAC10.html) | ||
| JP2023524493A5 (cg-RX-API-DMAC10.html) | ||
| JP2023515404A5 (cg-RX-API-DMAC10.html) | ||
| JP2023538949A5 (cg-RX-API-DMAC10.html) | ||
| JP2023513272A5 (cg-RX-API-DMAC10.html) | ||
| JP2023540558A5 (cg-RX-API-DMAC10.html) | ||
| US20230201185A1 (en) | Treatment of type 2 diabetes or obesity or overweight with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof | |
| RU2345067C2 (ru) | Ингибиторы дпп-iv | |
| JP2023540609A5 (cg-RX-API-DMAC10.html) | ||
| JP2025506473A5 (cg-RX-API-DMAC10.html) | ||
| US9382229B2 (en) | Compounds and methods of use thereof for treating neurodegenerative disorders | |
| US20240294525A1 (en) | Compounds as glp-1 receptor agonists and uses thereof | |
| JP7769695B2 (ja) | Glp-1rアゴニストの結晶形態およびその使用 | |
| US20170088532A1 (en) | Inhibitors of lpxc | |
| US20130023522A1 (en) | Benzamides | |
| CA2889697C (en) | Cannabinoid receptor mediating compounds | |
| CA2657350A1 (en) | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | |
| US9238074B2 (en) | Crystalline forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid | |
| JP2009501776A (ja) | 遊離脂肪酸に起因した障害におけるチアゾール誘導体およびアナログの使用 | |
| JP2010504321A5 (cg-RX-API-DMAC10.html) | ||
| TW201418250A (zh) | 含有雜環的5-羥基吲哚類衍生物及其用途 | |
| CN117337281A (zh) | 作为可溶性环氧化物水解酶抑制剂的哌啶脲衍生物 | |
| JP3410476B2 (ja) | 新規なエポキシコハク酸アミド誘導体又はその塩 | |
| CN1228325C (zh) | 双胍衍生物 |